Biocelect Pty Ltd is a privately owned, full-service Australian pharmaceutical company. We work with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market. Our priority areas include infectious diseases, specialty care and in-vitro diagnostics, a portfolio that also enables us to support the Australian Government and key organisations in emergency health planning.
In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand. We are proud to play an important part in our Governments’ COVID-19 management plans by providing options for the vaccine program rollout.
Biocelect aims to utilise our SME agility and broad industry experience to enable access to products that meet the needs of our patients and partners. We do this by providing a range of bespoke partnering solutions for companies wanting to ensure access of their products to patients in our region. Biocelect has an experienced team with extensive multinational experience across multiple therapy areas. We also draw on the experience of our sister company, Biointelect, www.biointelect.com and their cross functional and experienced biopharmaceutical and MedTech industry staff. This allows Biocelect the ability to provide the functionality of a larger company to partners, without losing our SME focus in driving the success of our products, always with the right patient in mind.